OTCMKTS:NVTRQ Nuvectra (NVTRQ) Stock Price, News & Analysis $0.02 -0.01 (-25.00%) As of 06/2/2020 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Nuvectra Stock (OTCMKTS:NVTRQ) Get Nuvectra alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$0.0150▼$0.015052-Week Range$0.01▼$4.30Volume382,600 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Nuvectra Corp is a medical device company focused on the development and commercialization of neuromodulation therapies for chronic pain management. The company’s flagship product, the Freedom® Spinal Cord Stimulation (SCS) System, is designed to deliver electrical pulses to the spinal cord via implantable leads and an implantable pulse generator (IPG). The system incorporates wireless recharging capabilities and physician-programmable stimulation parameters, enabling tailored pain relief for patients who have not responded adequately to conservative treatments such as medication or physical therapy. Nuvectra received FDA approval for its Freedom SCS System in 2015 and subsequently launched the product in the United States through a direct sales force and partnerships with select distributors. The company also pursued regulatory clearances and limited market access in international jurisdictions. In April 2018, Nuvectra filed for Chapter 11 bankruptcy protection and subsequently sold its assets. Its remaining equity now trades on the OTC Pink market under the ticker NVTRQ, reflecting the company’s transformed status post-restructuring. Throughout its operational history, Nuvectra built a leadership team with experience in medical technology, regulatory affairs, and clinical research to support product development and patient outcomes. Although the company’s restructuring curtailed ongoing R&D activities, the Freedom SCS System represented a notable advancement in implantable neuromodulation platforms, particularly in its focus on programmability and patient comfort. Nuvectra’s legacy in the spinal cord stimulation space continues to inform new approaches to chronic pain therapy within the broader medical device industry.AI Generated. May Contain Errors. Read More Receive NVTRQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvectra and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVTRQ Stock News HeadlinesImasen Electric Industrial Co Ltd (7266)August 1, 2023 | investing.comGlobal Nerve Repair & Regeneration Market (2021 to 2026) - by Product, Application and Geography - Benzin - BenzingaMarch 4, 2022 | benzinga.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.May 19 at 1:00 AM | Banyan Hill Publishing (Ad)Outlook on the Nerve Repair & Regeneration Global Market to 2026 - Featuring Medtronic, Abbott Laboratories and LivaNova Among Others - ResearchAndMarkets.com - Business WireMarch 2, 2022 | businesswire.comInteger Holdings Corporation Reports Results for Fourth Quarter and Full Year 2021 - GlobeNewswireFebruary 17, 2022 | globenewswire.comInteger Holdings Corporation Reports Results for Fourth Quarter and Full Year 2021 - StockhouseFebruary 17, 2022 | stockhouse.comGlobal Bioelectric Medicine Market (2020 to 2030) - by Product Type, End-user and Region - Benzinga - BenzingaFebruary 15, 2022 | benzinga.comGlobal Spinal Cord Stimulation Market (2021 to 2026) - by Product, Disease, End-user and Geography - GlobeNewswireFebruary 8, 2022 | globenewswire.comSee More Headlines NVTRQ Stock Analysis - Frequently Asked Questions How have NVTRQ shares performed this year? Nuvectra's stock was trading at $0.0150 at the beginning of 2026. Since then, NVTRQ shares have increased by 0.0% and is now trading at $0.0150. How were Nuvectra's earnings last quarter? Nuvectra Corporation (OTCMKTS:NVTRQ) released its quarterly earnings results on Monday, October, 29th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.01. The business had revenue of $14.22 million for the quarter, compared to the consensus estimate of $12.38 million. How do I buy shares of Nuvectra? Shares of NVTRQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings10/29/2018Today5/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolOTCMKTS:NVTRQ Previous SymbolNASDAQ:NVTRV CIK1648893 Webwww.nuvectramed.com Phone214-474-3103FaxN/AEmployees197Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:NVTRQ) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectra Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectra With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.